424   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Abstract  
 Alzheimer disease debilitating progressive neurodegenerative disorder characterize 
 progressive accumulation abnormal protein include amyloid plaque 
 intracellular tau tangle primarily brain lysosome crucial intracellular 
 organelle responsible protein degradation play key role maintain cellular 
 homeostasis study suggest link dysregulation 
 lysosomal system pathogenesis neurodegenerative disease include Alzheimer 
 disease restore normal physiological function lysosome hold potential 
 reduce pathological burden improve symptom Alzheimer disease 
 currently efficacy drug treat Alzheimer disease limit major 
 challenge drug delivery efficiency targeting recently nanomaterial gain 
 widespread use Alzheimer disease drug research owe favorable physical 
 chemical property review aim provide comprehensive overview recent 
 advance nanomaterial polymeric nanomaterial nanoemulsion carbon- 
 base nanomaterial enhance lysosomal function treat Alzheimer disease 
 review explore new concept potential therapeutic strategy Alzheimer 
 disease integration nanomaterial modulation lysosomal function 
 conclusion review emphasize potential nanomaterial modulate lysosomal 
 function improve pathological feature alzheimer disease application 
 nanotechnology development alzheimer disease drug bring new idea 
 approach future treatment disease 
 Key Words alzheimer disease autophagy dysfunction lysosomal acidification lysosomal 
 system nanomaterial neurodegenerative disease 
 Introduction 
 Alzheimer disease ad common form dementia 
 old individual currently mainstay ad treatment 
 involve medication target cholinergic glutamatergic 
 neurotransmission central nervous system 
 crucial note treatment provide symptomatic 
 relief cure underlying cause ad remain 
 unclear characterize accumulation 
 amyloid-β aβ plaque formation neurofibrillary tangle 
 result tau protein hyperphosphorylation twarowski 
 Herbet 2023 lysosome responsible remove abnormal 
 protein believe play central role development 
 neurodegenerative disorder ad Parkinson disease 
 pd tow impaired lysosomal activity Van Acker et 
 al. 2019 recent research reveal decline autophagy 
 function individual ad occur prior 
 initial accumulation aβ plaque neuronal cell 
 study show observe aβ plaque brain 
 result neuronal death cause accumulation 
 dysfunctional autophagosome condition autophagic 
 stress Lee et al. 2022 finding provide novel avenue 
 pharmacological investigation context ad 
 lysosomal system function primary conduit 
 degradation biological macromolecule 
 protein lipid nucleic acid polysaccharide related 
 compound Wang et al. 2018 Chen et al. 2022 cellular 
 composition encompass diverse array hydrolytic enzyme 
 crucial uphold structural integrity protein 
 macromolecule cellular milieu system comprise 
 early intranucleosome late intranucleosome circulate 
 intranucleosome lysosome lai et al. 2021 typical 
 circumstance constituent function facilitate 
 efficient breakdown macromolecule particularly protein 
 pathogenesis ad involve multiple abnormality 
 1department Neurology Second affiliated Hospital Naval Medical University Shanghai Changzheng Hospital Shanghai China 2school Health Science 
 Engineering University Shanghai Science Technology Shanghai China 3Changhai Clinical Research Unit Shanghai Changhai Hospital Naval 
 Medical University Shanghai China 4department Clinical Pharmacy Xinhua Hospital Shanghai Jiao Tong University School Medicine Shanghai China 
 5department Neurology Shanghai East Hospital School Medicine Tongji University Shanghai China 
 Correspondence Yin phd yinyou179@163.com Jie Gao phd jmsx2021@shu.edu.cn Yan Liu phd liuyan@shsmu.edu.cn 
 https://orcid.org/0000 0001 9657 9720 Yin 
 author contribute equally work 
 Funding work support Natural Science Foundation Shanghai No. 22zr147750 science Technology Innovation Action Plan Shanghai 
 Science Technology Commission No. 23y11906600 Shanghai Changzheng Hospital Innovative Clinical Research Project no. 2020YLCYJ-Y02 yy 
 cite article Hao M Chu J Zhang T Yin t Gu Y Liang W Ji W Zhuang J Liu Y Gao J Yin y 2025 nanomaterials-mediated lysosomal regulation 
 robust protein-clearance approach treatment alzheimer disease neural Regen Res 20(2):424 439 
 Contents 
 Introduction 
 424 
 Retrieval Strategy 
 425 
 Alzheimer disease lysosomal Dysfunctions 
 Pathogenesis therapeutic intervention 
 425 
 nanomaterial target Lysosomal Strategies 
 427 
 downstream Changes target lysosomal Therapy 
 432 
 Conclusion Outlook 
 434 
 nanomaterials-mediated lysosomal regulation 
 robust protein-clearance approach treatment 
 Alzheimer disease 
 https://doi.org/10.4103/NRR.NRR-D-23 01736 
 Date submission October 22 2023 
 Date decision January 4 2024 
 Date acceptance February 20 2024 
 Date web publication April 3 2024 
 Mengqi hao1 2 jianjian chu1 Tinglin zhang3 Tong Yin1 Yuankai gu1 Wendanqi liang1 2 Wenbo Ji1 Jianhua zhuang1 
 Yan liu4 Jie gao3 yin1 5 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜425 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 lysosomal system dramatic impact onset 
 progression ad Whyte et al. 2017 Klein Hermey 
 2023 consequently understand role lysosome 
 pathogenesis ad essential therapeutic intervention ad 
 nanomaterial entity dimension measure < 100 nm 
 find extensive application treatment ad owe 
 exceptional surface impact durability Bukhari 2022 
 subset nanomaterial ability selectively aggregate 
 lysosome facilitate repair lysosomal damage 
 restoration optimal lysosomal ph lo Zeng 2023 
 nanomaterial hold promise treat ad capacity 
 degrade pathogenic protein decrease neuroinflammation 
 potential therapeutic effect Unnisa et al. 2023 
 term target lysosomal therapy ad certain 
 review explore advancement utilize 
 small-molecule drug good knowledge 
 currently all-encompassing methodical compilation 
 nanomaterial target lysosomal system 
 comprehensive review classification underlie 
 mechanism action important provide 
 comprehensive overview encompass advancement 
 challenge encounter field nanomaterial 
 article aim present comprehensive analysis 
 nanomaterial specifically design target lysosome 
 type nanomaterial document scientific 
 literature potential candidate target lysosome 
 management ad nanomaterial include polymeric 
 nanomaterial carbon-based nanomaterial nanoemulsion 
 ne possess ability traverse blood brain 
 barrier bbb subsequently restore lysosomal functionality 
 inside cell discourse examine correlation 
 lysosome-associated damage progression 
 ad provide overview circumstance 
 lysosomal injury contribute development 
 disease additionally focus advancement 
 utilization nanomaterial specifically target lysosome 
 treatment management neurodegenerative disorder 
 include ad figure 1 furthermore propose 
 approach utilize nanomaterial management ad 
 technique include removal pathogenic protein 
 suppression neuroinflammation preservation neuronal 
 function section discuss challenge 
 potential prospect associate utilization lysosome- 
 target nanomaterial management ad 
 Retrieval Strategy 
 1 2023 September 30 2023 search 
 relevant literature pubmed database search subject 
 term include following Alzheimer disease lysosome 
 neurodegenerative disease nanomaterial blood- 
 brain barrier neuroprotection neuroinflammation 
 combination search term 
 comprehensively review literature article related ad 
 lysosome nanomaterial screen title 
 abstract access alzforum https://www.alzforum 
 org/ identify ongoing clinical trial anti-inflammatory 
 treatment ad 
 Alzheimer disease lysosomal Dysfunctions 
 Pathogenesis therapeutic Interventions 
 Neurodegenerative malady commonly characterize 
 accumulation misfolde protein degeneration 
 neuron specific area brain Autophagy 
 cellular mechanism responsible destruction 
 macromolecule cell serve crucial channel 
 elimination faulty protein organelle particularly 
 nervous system mammal Malampati et al. 2020 
 process involve sequestration protein damage 
 organelle lysosome rely heavily proper 
 functioning lysosome Krishnan et al. 2020 shojaei et al. 
 2020a b lysosome play vital role intracellular organelle 
 contain 60 proteolytic enzyme responsible 
 degradation protein nucleic acid endogenous 
 foreign biomolecule Chen et al. 2022 essential 
 maintain intracellular protein homeostasis stability 
 serve primary intracellular digestive compartment 
 growing evidence suggest lysosomal dysfunction play 
 crucial role development progression ad Van 
 Acker et al. 2021 Li et al. 2022 Udayar et al. 2022 
 figure 1 ｜nanomaterial 
 synthesis delivery 
 targeting lysosome 
 nanomaterial treatment 
 ad involve treating 
 inject nanomaterial 
 body access ad-affected 
 area brain 
 BBB inside cell 
 nanomaterial reach 
 lysosome restore 
 normal lysosomal function 
 enhance cellular autophagy 
 facilitate removal 
 pathological protein create 
 biorender.com ad 
 Alzheimer disease bbb blood– 
 brain barrier sirna small 
 interfering rna 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 426   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Dysfunction lysosome 
 Lysosomes acidic organelle contain enzyme 
 hydrolyze digest macromolecule intracellularly 
 play critical role cellular function koh et al. 2019 
 tian et al. 2022 lysosomal acidification crucial proper 
 functioning enzyme regulate acidity lysosome 
 involve coordinate activity multiple ion channel 
 particular emphasis vacuolar atpase v-atp Root 
 et al. 2021 macromolecular complex actively transport 
 proton h+ lysosome lower ph lysosomal 
 lumen need acidic level acidic environment 
 essential activation numerous hydrolytic enzyme 
 lysosome optimize efficiency ph- 
 dependent mechanism Colacurcio Nixon 2016 ph 
 lysosomal lumen maintain range 6.5–4.5 
 contrast normal cytoplasmic ph range 
 7.2 7.4 atp-dependent proton pump located 
 lysosomal membrane responsible maintain ph 
 lysosomal lumen Hu et al. 2022 malfunctioning 
 v-atp complex lead impaired lysosomal acidification 
 affect function lysosomal tissue phosphatase McGuire 
 et al. 2017 result abnormal protein accumulation severe 
 neuronal complication lipid oxidation reactive oxygen specie 
 formation Lee et al. 2010 impaired substrate digestion 
 contribute development neurodegenerative disease 
 related study ad propose presenilin 
 1 psen1 knockout mouse exhibit reduce expression 
 v-atpase subunit v0a1 defective v-atpase enzyme lead 
 lysosomal alkalinization increase ca2 + release Lee et 
 al. 2010 2015 Filadi Pizzo 2019 study show 
 presenilin 1 ps1 presenilin 2 ps2 double knockout 
 cell reduce ca2 + level affect lysosome-autophagosome 
 fusion Coen et al. 2012 additionally Mustaly-Kalimi et al. 
 find dysregulation intracellular ryanodine receptor- 
 ca2 + homeostasis lead impaired lysosomal deacidification 
 protein clearance Mustaly-Kalimi et al. 2022 result 
 suggest ca2 + dysregulation strongly associate ad 
 Lysosomes contain diverse range enzyme hydrolyze 
 protein substrate effectiveness 
 protease compromise cellular stressor 
 endoplasmic reticulum stress oxidative stress lead 
 impaired lysosomal degradation process colacurcio et 
 al. 2018 mutation cathepsin b cstb gene 
 potential disrupt protein cleavage lysosome 
 cathepsin group enzyme responsible protein 
 degradation lysosome abnormality cstb gene 
 result excessive secretion cystatin b inhibit cathepsin 
 activity impair hydrolytic clearance protein 
 lysosome result significant accumulation aβ 
 lysosome lead buildup intralysosomal aβ 
 deposition aβ extracellularly Yang et al. 2011 lai et al. 2021 
 cstb gene responsible store cystatin b lysosomal 
 cysteine protease inhibitor cathepsin impair 
 lysosomal function contribute development ad 
 accordance requirement β-site amyloid-β a4 
 precursor protein-cleaving enzyme 1 bace1 locus lysosome 
 contain enzyme regulate promote amyloidogenic 
 process membrane type 1 matrix metalloproteinase Van 
 Acker et al. 2021 membrane type 1 matrix metalloproteinase 
 located upstream bace1 locus accelerate cleavage 
 bace1 promote amyloidogenic protein production Liao 
 Van Nostrand 2010 lysosomal enzyme play 
 instrumental role pathogenesis amyloidosis 
 Lysosomes production Aβ 
 Aβ deposition entail core ad pathophysiology research 
 indicate formation Aβ result cleavage 
 amyloid precursor protein app certain enzyme 
 split neuron neurogenesis synaptic function apoptosis 
 cell proliferation multiple event app 
 implicate Milosch et al. 2014 Fanutza et al. 2015 Cho et al. 
 2022 similar functional protein human body 
 APP undergo swift synthesis cycle endoplasmic 
 reticulum synthesis app promptly encounter conveyance 
 Golgi apparatus cellular organelle responsible 
 encapsulation vesicle synthesize app follow 
 separate processing pathway non-amyloidogenic 
 pathway amyloidogenic pathway Wang et al. 2017 
 amyloidosis pathway app undergo initial cleavage 
 β-secretase know bace1 lead formation 
 type app β-c-terminal fragment app-βctf intermediate 
 byproduct cleave γ-secretase lead 
 increase aβ level Salminen et al. 2013 study reveal 
 app-βctf pathologically activate rab5 binding 
 adaptor protein contain pleckstrin homology domain 
 phosphotyrosine binding domain leucine zipper motif 
 appl1 early endosome Colacurcio et al. 2018 rab5 
 pathologically activate amyloidogenic pathway promote 
 early endosomal processing app lead increase 
 aβ production contribute ad 
 furthermore deletion sortilin-related receptor 1 sorl1 
 gene show impair lysosomal function sorl1 
 gene encode regulator involve protein transport 
 trans-golgi network endosome include app Andersen 
 et al. 2016 sorl1 gene absent neuronal 
 lysosomal ctsd activity significantly reduce lysosomal 
 clearance impaired autophagic vesicle accumulate app 
 translocate region endocytosis favorable 
 aβ production lead increase aβ production Dodson et 
 al. 2008 Hung Livesey 2021 Hung et al. 2021 
 reduce degradation aβ lysosome exacerbate 
 aβ accumulation caglayan et al. 2014 additional study 
 Sannerud et al. 2016 propose psen2/γ-secretase 
 mainly restricted late endosomes/lysosome important 
 establishment intracellular aβ pool familial 
 ad-presenilin 2 fad-psen2 mutation significantly increase 
 ratio intracellular aβ42/40 reveal important role 
 specific intracellular localized response pathogenesis 
 ad mutation app gene chr21 genetic 
 feature ad Li et al. 2021 50 highly pervasive 
 synapsis chr21 app susceptible 
 cleavage produce neurotoxic aβ1–42 accelerate 
 progression ad Cacace et al. 2016 reduce app 
 protein alleviate neuronal endolysosomal dysfunction cause 
 sorl1 deficiency suggest app play role 
 regulate endolysosomal system Hung et al. 2021 aβ 
 theory widely recognize pathogenesis ad 
 understanding aβ production crucial development 
 therapeutic approach ad selkoe Hardy 2016 
 Lysosomes accumulation tau 
 tau protein aggregated form substrate 
 lysosomal degradation Polito et al. 2014 impaired 
 lysosomal function contribute accumulation 
 misfolded/aggregated tau xu et al. 2021 suggest 
 lysosomal dysfunction accelerate accumulation 
 tau protein ad trigger release lysosomal calcium 
 turn promote pathological change tau protein Rao 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜427 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 et al. 2014 lead formation neurofibrillary tangle 
 furthermore lysosome biogenesis regulate transcription 
 factor eb tfeb Xue et al. 2023 recent evidence suggest 
 tfeb facilitate clearance pathogenic protein 
 associate ad regulate cytoplasmic distribution 
 nuclear translocation lysosome Li et al. 2022 notably 
 retromer critical maintain lysosomal function 
 tau protein clearance retromer multimodular protein 
 assembly vacuolar protein sorting-associated protein 
 35 vps35 backbone molecule retrotransporter 
 complex scaffold retrotransporter complex 
 module receptor binding small Petsko 2015 
 show lysosomal degradation reduce vps35 
 knockout hela cell lysosomal targeting vitro activity 
 β-galactosidase decrease Cui et al. 2019 autophagic 
 flux notably reduce vps35-deficient cell 
 impaired lysosomal protein hydrolysis increase 
 microtubule-associated protein tau (mapt)/tau aggregation 
 Carosi et al. 2021 addition tfeb remove 
 mapt autophagy/lysosomal system remodeling 
 chaperone-mediated autophagy Binder et al. 2020 Gorantla 
 Chinnathambi 2021 addition above-mentioned 
 tau-related specie app closely associate tau 
 pathology ad Dave et al. 2023 increase app lead 
 tau mislocalization accumulation mislocalize tau 
 protein form protofibrillar seed multiplie result 
 vicious cycle accumulation tau protein suggest 
 excess app ad brain correlate tau pathology ad 
 Kametani Hasegawa 2018 Dave et al. 2023 
 potential therapeutic approach ad involve strategy 
 restore enhance lysosomal function efficacy 
 current drug limit BBB lack 
 specific targeting capability nanodose enable site-specific 
 delivery improve drug solubility Hettiarachchi et al. 2019 
 enhance therapeutic efficacy target lysosome 
 nanomaterial target Lysosomal Strategies 
 Nanomaterials create new wave medical field 
 offer new hope patient ad suffer 
 challenging disease distinct characteristic e.g. small size 
 high targeting preferred recipient target- 
 drug delivery precise treatment diseased area brain 
 section outline current strategy nanomaterial 
 targeting lysosome 
 nanomaterial modify lysosomal fiber inspire 
 potent utility investigation cure debilitate neural 
 degenerative disorder depend carrier material 
 nano-drug delivery system broadly classify 
 category organic inorganic nanomaterial link 
 biomolecule ligand specific targeting figure 2 
 Karthivashan et al. 2018 Gupta et al. 2019 summary 
 focus development nanomaterial target 
 lysosome treatment ad table 1 provide overview 
 application different nanomaterial ad 
 nanomaterial BBB 
 BBB serve crucial protective layer brain act 
 metabolic transport barrier shield 
 potentially hazardous signal framework encompass 
 brain capillary endothelial cell neuroglial cell 
 interconnected tight junction endothelial cell bind 
 basolateral membrane cap end-foot glial 
 astrocyte subject continuous monitoring microglia 
 Zenaro et al. 2017 Zhao et al. 2021 result limited 
 paracellular transport allow passage small 
 hydrophilic molecule ion additionally transportation 
 pathway lipid confirm sánchez-navarro et al. 2017 
 multiple infrastructure notably carrier-mediated transcytosis 
 receptor-mediated transport cell-mediated endocytosis 
 adsorptive transcytosis facilitate transportation vital 
 component brain particular channel Chen 
 Liu 2012 Gao 2016 bbb pose significant obstacle 
 effective management ad efficacy ad 
 necessitate transportation therapeutic agent 
 BBB prohibit approximately 98 upcoming 
 neuropharmaceutical penetrate brain gregori 
 et al. 2015 Yin et al. 2023a contrast nanomaterial 
 tackle dilemma effectively penetrate bypass 
 BBB facilitate drug delivery brain appropriate 
 modification boost efficiency stability drug 
 delivery Chu et al. 2022 woon et al. 2022 Anwar et al. 2023 
 Figure 3 
 polymeric nanoparticle 
 retention organic synthetic polymeric 
 nanomaterial feasible polymeric nanomaterial 
 chemically synthesize emulsification salt precipitation 
 nanoprecipitation masood 2016 polymeric nanomaterial 
 exhibit high drug-loading capacity minimal toxicity 
 
 b 
 Figure 2 ｜nanomaterial 
 treating ad 
 effective 
 nanotherapeutic nanomaterial 
 ad reproduce 
 permission Karthivashan et 
 al. 2018 b method 
 nanomaterial synthesis 
 reproduce permission 
 Gupta et al. 2019 
 Copyright 2019 Elsevier B.V. 
 right reserve ad alzheimer 
 disease np nanoparticle 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 428   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Table 1 ｜application nanomaterial ad therapy 
  sort 
 Size 
 nm 
 Framework 
 Feature 
 Efficacy ad 
 Route 
 administration/ 
 model system 
 Translational/ 
 clinical trial 
 Transparent 
 BBB 
 Reference 
 liposomal np 
 25– 
 10000 
 Spherical 
 structure 
 phospholipid 
 bilayer 
 Nontoxic 
 nonimmunogenic 
 easy target 
 aβ clearance 
 acetylcholine lipase 
 inhibition 
 intravenous 
 injection/sprague- 
 Dawley rat 
 bend.3 cell 
 primary rat glia 
 primary rat 
 neuronal cell 
 wo 2014 
 076709a1 
 conjugate 
 cell-penetrating 
 peptide 
 tat pvec 
 QL 
 Agrawal et al. 
 2017 Dos Santos 
 Rodrigues et al. 
 2019 
 Polymer np 
 10–300 multiple 
 configuration 
 Excellent 
 biocompatibility 
 
 biodegradability 
 Immunomodulatory 
 antioxidant anti- 
 inflammatory 
 intranasal 
 delivery/16hbe 
 cell sh-sy5y cell 
 
 Coupled Lf 
 Ouyang et al. 
 2017 Meng et 
 al. 2018 Aliev et 
 al. 2019 
 Carbon base 
 np 
 1–1000 Polyhedral 
 carbon structure 
 seamless tubular 
 structure 
 Superior chemical 
 physical 
 electronic 
 property 
 Antioxidant 
 neuroprotective 
 scavenging Aβ 
 intravenous 
 injection/sh-sy5y 
 cell Wistar rat 
 
 receptor- 
 mediated 
 pathway 
 Lohan et al. 
 2017 Mohajeri 
 et al. 2019 
 Elsori et al. 2023 
 Nanoemulsion 
 50– 
 1000 
 Orbicular 
 Nontoxic 
 nonirritating 
 highly 
 biocompatible 
 dose dependent 
 cytotoxicity 
 antioxidant activity 
 intravenous 
 injection/be (2)- 
 m17 human 
 neuroblastoma 
 267/KOLNP/2007 combine 
 nls 
 Cunha et al. 
 2020 Agrawal et 
 al. 2021 Ansari 
 et al. 2023 
 ad alzheimer disease aβ amyloid-β bbb blood brain barrier lf lactoferrin nl nucleolipid NP nanoparticle pvec vascular endothelial-cadherin-derived 
 peptide ql hydrophobic pentapeptide qlpvm tat trans-activator transcription 
 Figure 3 ｜nanomaterial transportation pathway 
 schema pathway involve transportation 
 nanomaterial blood brain barrier reproduce 
 permission Karthivashan et al. 2018 np nanoparticle 
 notably toxicity reduce polyethylene glycol 
 (peg)-phospholipid copolymer Hettiarachchi et al. 2019 
 Polyhydroxyalkanes polylactide-co-glycolide plga cyclodextrin- 
 derive peg-coated polymeric nanomaterial widely 
 brain research nanoscale carrier context 
 ad therapy plga pegylated polymeric nanomaterial 
 commonly encounter masood 2016 plga synthetic 
 hydrophobic polyester compose monomer derive 
 lactic acid glycolic acid monomer assemble 
 randomly block copolymer legalization plga 
 U.S. Food Drug Administration credit 
 extraordinary biocompatibility biodegradable property 
 biosafety adaptability make finest polymer 
 field biomedicine martin et al. 2018 plga micro/ 
 nanomaterial utilize drug delivery system 
 wide range small molecule molecule include 
 pharmaceutical physiologically active compound 
 therapeutically relevant molecule assist management 
 disease Rezvantalab et al. 2018 Essa et al. 2020 
 Bourdenx et al. 2016 provide evidence plga-based 
 nanomaterial induce change lysosomal function 
 multiple cellular model pd include toxic genetic model 
 cellular uptake nanomaterial subsequent 
 targeting lysosome thoroughly investigate 
 Bourdenx study Bourdenx et al. 2016 fibroblast derive 
 patient pd carry lysosome‐related transmembrane 
 p5‐type atp transportase atp13a2 mutation treat 
 plga-based nanomaterial comparison 
 normal human fibroblast result demonstrate 
 treatment plga-based nanomaterial successfully restore 
 lysosomal ph normal level figure 4a immunoblotting 
 reveal decrease accumulation microtubule- 
 associated protein 1 light chain 3β-ii significantly enhance 
 clearance autophagosome Figure 4b functional assay 
 confirm restoration lysosomal proteolytic activity 
 plga-based nanomaterial-treated fibroblast compare 
 untreated fibroblast figure 4c additionally breakdown 
 product plga consist lactic glycolic acid 
 ability modulate lysosomal ph level Cunha et al. 
 2021a primary focus publication 
 PD researcher provide evidence plga-based 
 nanomaterial exert effect clinical condition 
 recent study Wu et al. 2022 reveal use 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜429 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 plain plga drug agent inhibitory effect 
 aβ aggregation toxicity wu et al. 2022 utilize 
 primary mouse cortical neuron demonstrate plain plga 
 internalize energy-mediated clathrin-dependent/- 
 independent pathway accumulate endosomal- 
 lysosomal-autophagic vesicle study Paul et al. 
 2022 provide evidence plga nanomaterial inhibit 
 Aβ aggregation induce disintegration aβ aggregate 
 nonphysiological temperature nanomaterial 
 show protect neuron detrimental 
 effect aβ-induced toxicity finding validate unique 
 therapeutic capability plga nanomaterial combat 
 pathological mechanism associate dementia figure 
 4d plga conjugation inhibit spontaneous aggregation 
 promote disassembly temperature 27–40 ° c 
 figure 4e additionally Wang et al. 2020 report PLGA 
 protect primary cortical neuron aβ toxicity time 
 attenuating lysosomal membrane permeability furthermore 
 protective effect plga aβ-induced toxicity 
 accompany reduce activation extracellular-signal related 
 kinase 1/2 glycogen synthase kinase figure 4f g 
 decrease level phosphorylate cleave tau protein 
 cleave caspase-3 Figure 4H Wang et al. 2020 
 study Govindarajan Kar Govindarajan Kar 2023 
 confirm PLGA recognize aβ neurotic plaque 
 ad mouse demonstrate potential plga treatment 
 diagnosis ad extensive research conduct 
 past decade explore use plga nanomaterial 
 innovative therapeutic approach neurodegenerative 
 disorder include ad available result far indicate 
 drug-loaded plga nanomaterial potential 
 treatment neurodegenerative disease despite 
 approval plga U.S. Food Drug Administration 
 drug-controlled release carrier currently clinical 
 application plga management neurodegenerative 
 disease research need 
 plga widely study ad therapeutic 
 high biocompatibility low toxicity good tissue permeability 
 targeting property ege 2021 PLGA nanomaterial 
 drawback limitation report 
 small-sized plga cross BBB efficiency 
 drug reach pathological region brain low Huang 
 et al. 2017 additionally high production cost plga 
 conducive drug development commercialization Rocha 
 et al. 2022 comprehensive investigation need 
 maximize clinical efficacy plga nanomaterial 
 therapeutic management ad 
 Figure 4 ｜ polymeric nanomaterial 
 revive lysosomal fiber 
 regular recombinant ATP13A2 
 l3292 stromal lysosomal ph 
 plga-anps measure b 
 altered ATP13A2 l3292 oocyte 
 plga-anps analyze 
 immunoblotting c probe 
 functioning ctsd normal defective 
 atp13a2 stromal lysosome p < 0.05 vs. 
 control untreated cell p < 0.05 vs. l3292 
 untreated cell c reproduce 
 permission Bourdenx et al. 2016 
 Copyright 2016 Taylor Francis d 
 temperature-dependent aβ aggregation 
 attenuate unconjugated plga 
 e dynamic light scattering analysis 
 perform aggregate aβ1–42 
 population 72 hour incubation 
 27 ° c 37 ° c 40 ° c 
 25 μm plga d e reproduce 
 permission Paul et al. 2022 
 F g phosphorylated erk1/2 gsk-3β 
 level induce aβ1–42 attenuate 
 200 μg/ml plga treatment h 
 caspase-3 phospho-tau cleave tau 
 level increase p < 0.05 p < 0.01 
 f h reproduce permission 
 Wang et al. 2020 copyright 2020 
 John Wiley son ACTB β-actin anp 
 acidic nanoparticle atp13a2 atpase 
 type 13a2 aβ amyloid-β ctl control 
 ctsd cathepsin d erk1/2   extracellular- 
 signal related kinase 1/2 gsk-3β   glycogen 
 synthase kinase lc3b microtubule 
 associate protein 1 light chain 3 β p-erk 
 phospho-thr202/tyr204 extracellular- 
 signal related kinase 1/2 p-gsk gsk-3β 
 phospho-tyr216   glycogen synthase kinase 
 PLGA poly(dl-lactide-co-glycolide t-erk 
 total extracellular-signal related kinase 1/2 
 t-gsk total glycogen synthase kinase 
 
 b 
 c 
 d 
 e 
 F 
 g 
 h 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 430   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 carbon-based nanoparticle 
 carbon-based nanomaterial exist form include 
 carbon nanotube fullerene graphene carbon dot 
 carbon nanotube carbon dot commonly 
 adsorbent adsorption investigation augustine et al. 2017 
 Carbon nanotube characterize long cylindrical hollow 
 structure categorize single-walled nanotube 
 swcnts multi-walled nanotube base number 
 graphene sheet contain excellent physical property 
 carbon nanotube lead wide range application 
 vivo drug delivery yang et al. 2010 conduct study 
 evaluate pharmacological toxicological characteristic 
 swcnts drug delivery purpose cytotoxicity research 
 swcnts show compare lysosome 
 mitochondria produce reactive oxygen specie figure 5a 
 presence swcnts lead significant reduction loss 
 mitochondrial membrane potential observe confocal 
 laser scanning microscopy jc-1 fluorescent dye Figure 
 5b result suggest mitochondria target 
 organelle swcnt toxicity yang et al. 2010 find 
 SWCNT dosage 300 mg/kg reduce mitochondrial 
 cytotoxicity carefully control dosage consider 
 specific dosage requirement different organelle 
 prioritized uptake swcnts lysosome achieve 
 facilitate effective delivery acetylcholine 
 brain maintain safety parameter treatment 
 ad experimental model study Xue et al. 2014 
 investigate autophagy capability crnd8 animal 
 wild-type control impact single-walled carbon 
 nanotube swnt therapy autophagy competence isolate 
 primary glial cell figure 5c researcher perform 
 immunoblot analysis autophagy pathway marker 
 assess different stage autophagy pathway 
 stage include evaluate mechanistic target rapamycin 
 mtor activation state autophagosome formation 
 lc3-positive vesicle identification lysosomal functionality 
 examine lc3 p62 turnover cathepsin d maturation 
 lysosome acidification Figure 5D f finding study 
 suggest functionalize swnts effectively restore 
 proper autophagy function reverse abnormal mtor signaling 
 correct deficiency lysosomal proteolysis 
 facilitate elimination autophagic substrate figure 5 g 
 mechanism swnt improve autophagy 
 require study result provide conceptual 
 evidence nanoparticle np therapy autophagy injury 
 carbon-based nanomaterial possess excellent electrical 
 mechanical chemical property make valuable 
 medical field numerous study demonstrate 
 therapeutic potential carbon-based nanomaterial 
 treatment brain disorder Du et al. 2018 Wang et al. 2019 
 Chu et al. 2021 Yin et al. 2023b production cost 
 high difficult produce large scale 
 research need 
 ne 
 ne gelatinous dispersion compose immiscible fluid 
 stabilize surfactant droplet ne exhibit wide range 
 size 20 500 nm Figure 6a Liao et al. 2018 Karami 
 et al. 2019 ne classify different type 
 
 b 
 d 
 e 
 F 
 c 
 g 
 Figure 5 ｜carbon-base 
 nanomaterial ad 
 swcnts effect lysosome 
 ros production b swcnts 
 enhance green fluorescence 
 reduce red fluorescence 
 course incubation indicate 
 modification mmp b 
 reproduce permission 
 Yang et al. 2010 
 Copyright 2010 Elsevier Inc. 
 right reserve c 6e10 antigen 
 red glial gfap green 
 immunofluorescence wt 
 crnd8 glial cell d e western 
 blot analysis demonstrate lc3 
 p62 expression f Size 
 number lysosome p < 0.05 
 p < 0.01 vs. Ctrl p < 0.05 
 vs. wt c f reproduce 
 permission Xue et al. 
 2014 copyright 2014 American 
 Chemical Society g carbon- 
 base np treatment 
 ad create biorender 
 com ad alzheimer disease 
 Ctrl control gfap glial fibrillary 
 acidic protein lc3 microtubule- 
 associated protein 1 light chain 3 
 mmp mitochondrial membrane 
 potential rel relative ros 
 reactive oxygen specie swcnt 
 single-walled carbon nanotube 
 WT wild type 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜431 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 water-in-oil w/o oil-in-water o/w water-in-oil-in-wat 
 w/o/w depend composition material 
 arrangement internal external phase phase-to- 
 volume ratio φ play crucial role determine quantity 
 ne droplet observe instability system φ 
 represent relative volume inner outer liquid 
 different property 
 ne offer well kinetic stability nanomaterial 
 small size brownian motion dominate 
 gravitational force type ne o/w ne 
 commonly treat neurodegenerative condition 
 brain brouillard et al. 2021 develop lipid-based nucleic 
 acid nanomaterial o/w ne nucleolipid nls organic 
 compound compose lipid molecule covalently bond 
 precursor amino acid nucleobase nucleoside 
 nucleotide oligonucleotide study novel inorganic 
 compound compound 7 8) succinate group 
 5′ position palmitate arachidonate 3′ position 
 Figure 6b Brouillard et al. 2021 design synthesize 
 evaluate biologically lysosomal ph agonist Brouillard 
 et al. 2021 experimental result show nucleic acid-lipid- 
 base nanomaterial effective lower lysosomal 
 ph restore function lysosome subsequently 
 author undertake deep investigation synthesize 
 tetramer nl Brouillard et al. 2023 biological evaluation 
 show tetramer nl release succinic acid restore 
 optimal lysosomal ph. active concentration tetramer NL 
 reduce factor compare corresponding 
 monomer separate experiment Geoffrey prepare oil- 
 in-water ne plga encapsulate inside ne Figure 6C 
 Prévot et al. 2018 approach concentration 
 fluorescent plga nanomaterial increase 
 0.18 0.56 g/l Bourdenx et al. 2016 laboratory result 
 demonstrate ability NE-PLGA cross BBB penetrate 
 brain tissue ultimately localize lysosome brain 
 Figure 6d similarly NE-PLGA restore acidic ph level 
 cellular lysosome figure 6e table 2 provide example 
 ne delivery brain 
 application ne show promise reacidification 
 lysosome undergo acidification facilitate 
 restoration normal lysosomal function approach 
 hold potential management ad worth 
 Figure 6 ｜nanoemulsion govern lysosomal ph. 
 nanoemulsion system oil-in-water reproduce permission Karami et al. 2019 copyright 2019 Elsevier Ltd. right 
 reserved b synthetic pathway nucleolipid 7–8 b reproduce permission Brouillard et al. 2021 right reserve c 
 acidic nanoemulsion image TEM d colocalized immunofluorescence z-stack orthogonally project e plga salvage lysosomal 
 ph. c e reproduce permission Prévot et al. 2018 copyright 2018 American Chemical Society lamp1 lysosomal associate 
 membrane protein 1 ne nanoemulsion plga polylactide-co-glycolide rt room temperature tem transmission electron microscope 
 
 b 
 c 
 d 
 E 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 432   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 noting ne exhibit insufficient equilibrium lead 
 drug leakage storage impact overall 
 effectiveness drug delivery mediate ne 
 main aspect target lysosome 
 direct targeting drug lysosome receptor surface 
 endosome folate vascular endothelial growth factor 
 ldl transferrin receptor-mediated endocytosis 
 Gopalan et al. 2020 glucose cerebrosidase present 
 lysosome involve sphingolipid degradation 
 researcher extract recombinant enzyme modify 
 expose mannose residue inject body 
 receptor-mediated endocytosis successfully transport 
 enzyme lysosome sly vogler 2002 
 furthermore endosomal escape require ensure 
 drug escape lysosome prevent degradation 
 maintain integrity drug well efficacy 
 Sakhrani Padh 2013 current therapeutic agent target 
 lysosomal dysfunction mainly small-molecule drug e.g. 
 small molecule activate v-atpase function regulate tfeb 
 expression inhibit mtor signaling nanomedicine 
 Quick et al. 2023 study show c381 target 
 lysosome stimulate lysosomal acidification attenuate 
 lysosomal membrane permeability increase proteolysis Vest 
 et al. 2022 importantly c381 show permeate 
 BBB potential drug choice restore lysosomal 
 function treatment neurodegenerative disease Vest 
 et al. 2022 additionally en6 promising small-molecule 
 drug inhibit mammalian target rapamycin complex 
 1 mtorc1 stimulate lysosomal acidification induce 
 autophagy enhance cell clearance Chung et al. 2019 
 en6 off-target trigger 
 biological effect Chung et al. 2019 addition small- 
 molecule drug researcher develop nanodrug 
 target lysosome nanodrug localized 
 lysosome restore normal ph lysosome Brouillard et 
 al. 2021 nanomedicine increasingly treatment 
 neurodegenerative disease superior property 
 considerable challenge efficiency 
 penetrate BBB optimize chemical formulation 
 incorporate bbb-penetrating peptide crucial 
 nanomedicine brain targeting Huang et al. 2017 second 
 consistency nanomedicine size dispersion 
 related clinical translation nanomedicine 
 drug distribution reproducibility accordance Good 
 Manufacturing practice quality standard drug 
 downstream Changes target lysosomal 
 Therapy 
 pathological protein clearance 
 pathological characteristic associate ad involve 
 accumulation persistence aβ tau peptide 
 deposition protein play crucial role 
 progression ad target removal pathogenic 
 protein scavenging mechanism hold potential 
 therapeutic approach ad Yuyama et al. 2015 viswanathan 
 et al. 2012 investigate inhibitory effect z-phe-ala- 
 diazomethylketone cathepsin b l find 
 modestly inhibit enzyme lead increase lysosomal 
 cathepsin level low concentration nonpeptidic compound 
 sd1002 sd1003 evaluate irreversible inhibitor 
 cathepsin b derive z-phe-ala-diazomethylketone 
 compound find effective lysosomal modulator 
 induce protective scavenging response paired helical 
 filament τ aβ42 brain region include 
 hippocampus similar effect observe resveratrol 
 r find reduce accumulation aβ 
 plaque formation exert beneficial impact ad model 
 Vingtdeux et al. 2008 cathepsin lysosomal enzyme 
 involve aβ degradation presence resveratrol 
 nanomaterial potential act lysosomal modulatory 
 agent amelioration ad 
 autophagy-defective lysosomal dysfunction 
 postulate closely related aβ deposition protein 
 kinase mtor regulate activation macromolecular 
 Table 2 ｜ overview nanoemulsion central nervous system disease 
 Drug 
 Size nm 
 drug effect 
 Outcome 
 Reference 
 Risperidone 
 15.5–16.7 
 Antipsychotic 
 reduce drug effect dosage frequency 
 administration 
 Kumar et al. 2008b 
 olanzapine 
 20.1–23.6 
 Schizophrenia medication 
 reduce dosage frequency administration 
 maximize therapeutic index 
 Kumar et al. 2008a 
 ergoloid mesylate 
 submicron emulsion 
 108.5±34.3 
 Antioxidation 
 improve drug absorption reduce toxicity 
 Yu et al. 2009 
 Nimodipine 
 40–300 
 anti-dementia cerebral 
 vasospasm 
 reduce drug efflux clearance prolonged extend 
 release drug 
 Pathak et al. 2014 
 Chloramphenicol 
 100.12±4.35 
 anti-inflammatory 
 improved solubility targeting drug 
 Musa et al. 2013 
 Kaempferol 
 3.08±17.33 
 anti-inflammatory 
 antioxidant antibacterial 
 improved drug-loading capacity encapsulation efficiency Colombo et al. 2017 
 Zolmitriptan 
 42.93±1.53 
 suppress vasodilation 
 inflammation 
 improved drug delivery efficiency bioavailability 
 therapeutic efficacy 
 Abdou et al. 2017 
 Quetiapine 
 144±0.5 
 antipsychotic drug 
 increase drug solubility bioavailability 
 Boche Pokharkar 2017 
 Paroxetine 
 58.47±3.02 
 antidepressant anti- 
 anxiety 
 increase drug availability biology 2.57-fold 
 increase drug delivery rate 
 Pandey et al. 2016 
 curcumin 
 14.4–118.9 
 suppress Aβ sedimentation 
 inflammation 
 increase drug release penetration 
 Sood et al. 2014 
 Resveratrol 
 102±1.46 
 mitigation oxidize stress increase drug concentration target efficiency 
 brain 
 Pangeni et al. 2014 
 Selegiline 
 10.0±203.0 
 Neuroprotective 
 antioxidant 
 increase drug penetration improve behavioral activity 
 pd mouse 
 Kumar et al. 2016 
 Aβ amyloid-β pd parkinson disease 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜433 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 complex collaborate subcellular membrane form 
 autophagosome encapsulate cytoplasmic component 
 degradation lysosome dysfunctional mtor signaling 
 lead poor autophagy induction protein accumulation 
 Xue et al. 2014 propose administration SWNT 
 potential remedy ad-associated amyloidosis transgenic 
 mouse model crnd8 finding indicate SWNT 
 effectively rectify dysfunction related autophagy 
 reverse poor autophagy induction cause aberrant mtor 
 signaling reverse impairment lysosomal proteolytic 
 activity lead accumulation autophagic substrate 
 ballooning lysosome swnt restore normal cellular 
 autophagy clear faulty protein activate autophagy 
 effective approach remove pathological protein 
 commonly fight ad addition 
 restore normal autophagy nanomaterial reduce 
 level misfolde protein restore lysosomal membrane 
 integrity increase lysosomal membrane permeability lead 
 release lysosomal enzyme cytoplasm trigger 
 apoptosis gómez-sinte et al. 2016 Sarkar et al. 2020 
 show nanomaterial target lysosome 
 PLGA protect lysosomal membrane reduce level 
 misfolde protein cell Wang et al. 2020 Wu et al. 
 2022 furthermore accumulation aβ tau protein 
 central pathophysiological feature ad proteinopathie 
 characterize presence misfolde aggregate 
 protein lose normal physiological function 
 acquire neurotoxic property researcher focus 
 explore novel mechanism facilitate elimination 
 neurotoxic protein aim develop method 
 potentially mitigate onset slow progression ad 
 summary lysosomal dysfunction accumulation 
 misfolde protein common pathological feature ad 
 nanomaterial target lysosome remove pathological 
 protein reacidifye lysosome enhance cellular 
 autophagy provide effective treatment ad 
 inflammation modulation 
 Neuroinflammation physiological response occur 
 inside central nervous system response 
 pathogenic stressor contributory aspect include infection 
 trauma ischemia toxin aforementioned process 
 distinguish generation proinflammatory cytokine 
 chemokine furthermore procedure entail 
 secretion small molecular signaling molecule 
 prostaglandin nitric oxide infiltration 
 reactive oxygen specie generate innate immune cell 
 central nervous system cellular constituent primarily 
 implicate process encompass microglia astrocyte 
 essential constituent innate immune system 
 notably capillary endothelial cell infiltrate blood cell 
 contribute neuroinflammation particularly instance 
 biochemical mechanical impairment 
 BBB Heneka et al. 2014 DiSabato et al. 2016 generation 
 proinflammatory molecule potential impede 
 synaptic dysfunction induce neuronal demise impact 
 neurogenesis Lyman et al. 2014 synaptic loss induce 
 interleukin (il)-1β mediate increase expression 
 prostaglandin e2 production result heightened release 
 presynaptic glutamate subsequent activation postsynaptic 
 n-methyl-d-aspartate receptor Mishra et al. 2012 add 
 activation complement system induce 
 enhancement microglia phagocytic function potentially 
 lead inappropriate synaptic pruning Hong et al. 2016 
 progression neuroinflammation substantial 
 quantity anti-inflammatory cytokine il-1 receptor 
 antagonist il-4 il-10 il-11 generate involvement 
 cytokine prevent excessive neuroinflammation 
 highlight existence complex regulatory system figure 
 7A Calsolaro Edison 2016 base current research 
 neuroinflammation evident collaborative interaction 
 microglia astrocyte neuron contribute 
 progression neurodegenerative process 
 accord vivo datum nanoformulation lead 
 reduction inflammation vilella et al. 2018 develop plga 
 system modify g7 glycopeptide deliver zinc 
 brain access brain increase zinc level system 
 effectively reduce presence proinflammatory cytokine 
 study Vilella et al. 2018 investigate effect zinc 
 level inflammation app23 mouse quantify level 
 il-6 il-18 tumor necrosis factor il-10 wild-type mouse 
 app23 mouse treat g7-nps saline solution app23 
 mouse treat zinc np researcher find evidence 
 suggest g7-nps-zn attenuate proinflammatory 
 response enhance production anti-inflammatory 
 cytokine exert counteractive effect 
 inflammatory mechanism body Figure 7B e additionally 
 Wu et al. 2022 observe application PLGA neuron 
 result downregulation transcript associate 
 mediate neuroinflammation e.g. interferon gamma il-1 
 alpha il-6 compare control Figure 7f 
 study nanomaterial reduce 
 neuroinflammation different pathway wide 
 range application treatment ad 
 nanomaterial inhibit neuroinflammation different 
 mechanism e.g. diminish cellular proinflammatory factor 
 increase level anti-inflammatory factor highly 
 prospective treatment ad 
 nanomaterial-mediated lysosomal autophagy 
 neuroprotection 
 prevalence ad increase age Soria Lopez et al. 
 2019 irreversible condition characterize 
 progressive degeneration eventual death neuronal 
 cell neurodegenerative disease currently treat 
 neuroprotective drug retard prevent 
 progression disease nanomaterial play crucial role 
 provide neuroprotective drug neurodegenerative disease 
 advantageous property small size 
 biocompatibility low cytotoxicity xi et al. 2022 Anwar et 
 al. 2023 study synthesize plga nanomaterial 
 encapsulate thymoquinone phytochemical molecule 
 know antioxidant anti-inflammatory effect 
 aim target specific aspect animal model elibol 
 et al. 2020 Yusuf et al. 2021 result demonstrate 
 thymoquinone provide neuroprotection reduce Aβ 
 plaque improve neuronal survival restore neuronal 
 activity additionally Xue et al. 2014 utilize swcnts treat 
 ad model mouse carbon nanotube exhibit high water 
 solubility dispersibility enhance cellular autophagic 
 flow property represent potential mechanism 
 neuroprotection achieve collectively 
 nanomaterial demonstrate ability protect neuron ad 
 mouse mitigate neuronal loss promote neuronal viability 
 research nanosize neuroprotective compound 
 early stage hold significant potential future 
 advancement pharmacology particularly treatment 
 neurodegenerative disease 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 434   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Conclusion Outlook 
 previously mention involvement lysosomal 
 dysfunction pathogenesis neurodegenerative disorder 
 implicate upregulation autophagy 
 observe compensatory response disease 
 Bordi et al. 2016 Hou et al. 2020 fully establish 
 lysosomal function impaired lysosomal dysfunction 
 emerge potential therapeutic target dementia- 
 related condition include ad pd Lee et al. 2010 Nixon 
 Yang 2012 consequently address lysosomal dysfunction 
 gain significant attention development therapeutic 
 intervention neurodegenerative disorder 
 nanomaterial enhance lysosomal function 
 effective treat ad clinical application remain 
 early stage study limit vitro animal 
 model challenge need overcome facilitate 
 clinical application nanomaterial 
 polymeric nanomaterial commonly material 
 PLGA plga rapidly clear reticuloendothelial system 
 reach brain ege 2021 prolong residence time 
 enhance brain transport coadministration plga peg 
 employ peg improve plga retention 
 body research necessary thoroughly investigate 
 delivery efficacy long-term toxicity pharmacokinetic 
 plga byproduct generate plga 
 degradation affect drug delivery brain Mir et al. 
 2017 precise role need elucidate second 
 utilization carbon-based nanomaterial ad therapy depend 
 address exist challenge associate 
 material experiment demonstrate potential 
 toxicity carbon nanotube induce oxidative stress 
 co-culture cell ensure high-quality carbon nanotube 
 minimizing contaminant pose significant challenge 
 translational application Elsori et al. 2023 
 researcher focus improve biocompatibility 
 safety carbon nanotube finally ne face great 
 challenge stable susceptible compromise 
 ph temperature Cunha et al. 2021b consider 
 lysosome reside acidic environment condition 
 impact stability efficiency ne drug delivery 
 experiment essential enhance stability ne 
 improve efficiency drug delivery 
 conclusion despite immense potential nanomaterial 
 target lysosome treatment ad challenge 
 address clinical translation include 
 optimize delivery efficacy safety profile polymeric 
 nanomaterial improve biocompatibility quality control 
 carbon-based nanomaterial enhance stability 
 efficiency ne drug delivery overcome challenge 
 nanomaterial-based therapy target lysosome offer 
 strategy treat ad neurodegenerative disorder 
 lysosomal acidification dysfunction commonly 
 observe neurodegenerative disease grow evidence 
 suggest lysosomal dysfunction potentially contribute 
 Figure 7 ｜nanomaterial suppress 
 neuroinflammation 
 glial cell physiological 
 function create 
 biorender.com b e treatment 
 animal zinc-loaded 
 nanomaterial alter inflammatory 
 marker p < 0.05 p < 0.01 b– 
 e reproduce permission 
 Vilella et al. 2018 copyright 
 2017 Elsevier gmbh. right 
 reserved f gene expression 
 24 hour plga treatment 
 show follow table f 
 reproduce permission 
 Wu et al. 2022 copyright 
 2022 publish Elsevier B.V. app 
 Amyloid precursor protein app23 
 heterozygous app23+/– transgenic 
 mouse g7 glycopeptide consist 
 seven amino acid hmbs 
 hydroxymethylbilane synthase NP 
 nanoparticle tnf-1 tumor necrosis 
 factor 1 wt wild type 
 
 b 
 d 
 e 
 F 
 c 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜435 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 development disease consequently target 
 lysosome emerge strategic focus potential 
 therapeutic intervention neurodegenerative disorder 
 ad study report 
 drug specifically target lysosomal ph few 
 study examine nanomaterial target lysosome 
 despite challenge face nanomaterial offer 
 new possibility approach drug development 
 neurodegenerative brain disease recent study 
 show nanomaterial functionalization peptide 
 effectively address issue low targeting efficiency 
 cytotoxicity example study d1 peptide 
 employ functionalize magnetic nanomaterial combined 
 chitosan-functionalized gold nanorod effectively reduce 
 cytotoxicity Hassan et al. 2018 multimerization 
 compound enhance drug delivery bioactivity 
 tolerability low concentration address multivalency 
 biological target nanomaterial functionalization 
 play crucial role development ad drug design 
 lysosome-targeted nanodrug researcher refer 
 aforementioned approach functionalize nanodrug 
 reduce drug toxicity improve targeting efficiency 
 objective advance development nanomaterial 
 possess characteristic low cytotoxicity enhance 
 targeting capability improve stability nanomaterial 
 intend treatment neurodegenerative disorder 
 particularly ad specifically target lysosome utilization 
 nanomaterial design target lysosome anticipate 
 significantly impact ad therapy thank advancement 
 material science synthesis methodology 
 recently nanomaterial bring renew hope treat 
 ad paper present detailed description type 
 nanomaterial target lysosome Figure 8) crucial 
 aspect ad therapy addition paper summarize 
 development target lysosomal drug figure 9 
 nanomaterial exhibit high cellular absorption mobility 
 Figure 8 ｜nanomaterial 
 therapeutic pathway 
 nanomaterial inject 
 mouse penetrate 
 blood brain barrier reach 
 cell diseased area 
 mouse brain reduce ph 
 lysosome restore cell 
 ability clear protein reduce 
 neuroinflammation protect 
 nerve cell create biorender 
 com il interleukin inos 
 inducible nitric oxide synthase NP 
 nanoparticle tnf-α tumor necrosis 
 factor-α 
 figure 9 ｜development 
 nanomaterial restore 
 lysosomal function ad therapy 
 create Microsoft PowerPoint 
 ad alzheimer disease ne 
 nanoemulsion nl nucleolipid 
 PLGA poly(dl-lactide-co-glycolide 
 swcnt single-walled nanotube 
 SWNT single-walled carbon 
 nanotube 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 436   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 passive targeting distinguish small compound 
 target lysosome preliminary finding application 
 lysosome-targeted nanomaterial disease include 
 lysosomal storage disease cancer neurodegenerative disease 
 autoimmune disease highlight therapeutic potential 
 intervention existing pharmaceutical treatment 
 neurodegenerative disease provide temporary relief 
 offer definitive cure utilization 
 nanomaterial specifically target lysosome hold promise 
 improve situation study anticipate contribute 
 comprehensive understanding field stimulate novel idea 
 development nanomaterial biomedical application 
 related lysosome intricacy lysosomal 
 function influence interaction central 
 nervous system cell necessitate research explore 
 complex relationship additionally drug targeting crucial 
 delivery review briefly describe target 
 modification nanomaterial topic extensively explore 
 require research 
 Author contribution manuscript design MH jc yl jz jg yy datum 
 retrieval tz ty yg wl wj jz yl manuscript preparation MH jc tz 
 yg manuscript review MH jc tz yl yg wj ty wl jz yy jg fund 
 acquisition yy jg author read approve final version 
 manuscript 
 conflict interest author declare conflict interest 
 data availability statement applicable 
 open access statement open access journal article 
 distribute term Creative Commons Attribution- 
 noncommercial-sharealike 4.0 License allow remix 
 tweak build work non-commercially long appropriate 
 credit give new creation license identical 
 term 
 reference 
 Abdou EM Kandil SM Miniawy h 2017 brain targeting efficiency 
 antimigrain drug load mucoadhesive intranasal nanoemulsion int j 
 Pharm 529:667 677 
 Agrawal M Ajazuddin Tripathi DK Saraf S Saraf S Antimisiaris SG Mourtas 
 S Hammarlund-Udenaes m Alexander 2017 recent advancement 
 liposome target strategy cross blood-brain barrier bbb 
 treatment alzheimer disease j Control Release 260:61 77 
 Agrawal M Prathyusha E Ahmed H Dubey SK Kesharwani p singhvi g Naidu 
 VGM Alexander 2021 biomaterial treatment alzheimer disease 
 Neurochem Int 145:105008 
 Aliev g Ashraf GM Tarasov VV Chubarev VN Leszek J Gasiorowski K 
 Makhmutovа Baeesa ss avila-rodriguez M Ustyugov AA Bachurin 
 2019 alzheimer disease 
 future therapy base dendrimer curr 
 Neuropharmacol 17:288 294 
 Andersen OM Rudolph IM Willnow TE 2016 risk factor sorl1 
 genetic association functional validation Alzheimer disease acta 
 Neuropathol 132:653 665 
 ansari MA tripathi t Venkidasamy b Monziani Rajakumar g Alomary MN 
 Alyahya SA Onimus O D’Souza N Barkat MA al-suhaimi ea Samynathan 
 r Thiruvengadam M 2023 multifunctional nanocarrier Alzheimer 
 disease befriend barrier Mol Neurobiol doi 10.1007/s12035 023- 
 03730-z 
 Anwar F al-abbasi FA Naqvi S Sheikh ra Alhayyani S Asseri AH asar 
 Kumar V 2023 therapeutic potential nanomedicine management 
 Alzheimer disease glioma int j Nanomedicine 18:2737 2756 
 Augustine S Singh J Srivastava M Sharma M Das malhotra bd 2017 
 recent advance carbon base nanosystem cancer theranostic 
 Biomater Sci 5:901 952 
 Binder JL chander p deretic V Weick JP Bhaskar K 2020 optical induction 
 autophagy transcription factor eb tfeb reduce pathological tau 
 neuron plos 15:e0230026 
 Boche M Pokharkar v 2017 quetiapine nanoemulsion intranasal drug 
 delivery evaluation brain-targeting efficiency aaps pharmscitech 
 18:686 696 
 Bordi M Berg MJ Mohan PS peterhoff cm alldred mj Che S Ginsberg SD 
 Nixon ra 2016 Autophagy flux ca1 neuron alzheimer hippocampus 
 increase induction overburden fail lysosome propel neuritic 
 dystrophy autophagy 12:2467 2483 
 Bourdenx M Daniel J Genin E Soria fn blanchard-desce m Bezard E Dehay 
 b 2016 nanoparticle restore lysosomal acidification defect implication 
 Parkinson lysosomal-related disease autophagy 12:472- 
 483 
 Brouillard M Barthélémy p Dehay b Crauste-Manciet S Desvergnes v 
 2021 Nucleolipid acid-based nanocarrier restore neuronal lysosomal 
 acidification defect Chem 9:736554 
 Brouillard M Kinet r Joyeux M Dehay b Crauste-Manciet S Desvergnes v 
 2023 modulate lysosomal ph innovative multimerized succinic 
 acid-based nucleolipid derivative bioconjug Chem 34:572 580 
 Bukhari SNA 2022 Nanotherapeutics Alzheimer disease preclinical 
 evaluation clinical trial challenge promise limitation curr 
 Drug Deliv 19:17 31 
 Cacace R Sleegers K Van Broeckhoven c 2016 molecular genetic early- 
 onset alzheimer disease revisit alzheimer Dement 12:733 748 
 Caglayan S Takagi-Niidome S Liao F Carlo Schmidt V Burgert t Kitago Y 
 Füchtbauer EM füchtbauer Holtzman dm Takagi J Willnow TE 2014 
 lysosomal sorting amyloid-β sorla receptor impair 
 familial Alzheimer disease mutation Sci Transl Med 6:223ra220 
 Calsolaro V Edison p 2016 neuroinflammation Alzheimer disease 
 current evidence future   direction alzheimer Dement 12:719 732 
 carosi JM Hein LK van den Hurk M Adams R Milky b Singh S Bardy c 
 Denton D Kumar S Sargeant tj 2021 Retromer regulate lysosomal 
 clearance mapt/tau autophagy 17:2217 2237 
 Chen C Sidransky E Chen Y 2022 lyso-ip uncover pathogenic 
 mechanism lysosomal dysfunction biomolecule 12:616 
 Chen Y Liu L 2012 modern method delivery drug blood- 
 brain barrier adv Drug Deliv rev 64:640 665 
 cho y bae hg Okun E Arumugam TV Jo DG 2022 physiology 
 pharmacology amyloid precursor protein pharmacol Ther 235:108122 
 Chu F Li K Li X Xu L Huang J Yang Z 2021 graphene oxide ameliorate 
 cognitive impairment inhibit pi3k/akt/mtor pathway induce 
 autophagy ad mouse model neurochem res 46:309 325 
 chu jj Ji WB Zhuang JH Gong BF Chen XH Cheng WB Liang WD Li gr Gao 
 J Yin y 2022 nanoparticles-based anti-aging treatment alzheimer 
 disease drug deliv 29:2100 2116 
 Chung CY shin hr Berdan Ford b Ward CC Olzmann JA Zoncu R 
 Nomura dk 2019 Covalent targeting vacuolar h(+)-atpase activate 
 autophagy mtorc1 inhibition nat Chem Biol 15:776 785 
 Coen K Flannagan RS Baron S carraro-lacroix LR Wang D Vermeire W 
 Michiels C Munck S Baert V Sugita S Wuytack F Hiesinger pr Grinstein 
 S Annaert W 2012 lysosomal calcium homeostasis defect proton 
 pump defect cause endo-lysosomal dysfunction psen-deficient cell j 
 Cell Biol 198:23 35 
 Colacurcio DJ Nixon ra 2016 disorder lysosomal acidification-The 
 emerge role v-atpase aging neurodegenerative disease ageing 
 res rev 32:75 88 
 Colacurcio DJ Pensalfini Jiang Y Nixon ra 2018 dysfunction autophagy 
 endosomal-lysosomal pathway role pathogenesis 
 syndrome Alzheimer disease free Radic Biol Med 114:40 51 
 Cui y Carosi JM Yang Z Ariotti N Kerr MC Parton RG Sargeant tj Teasdale 
 RD 2019 Retromer selective function cargo sorting endosome 
 transport carrier j cell Biol 218:615 631 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜437 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Colombo M Melchiades gl Figueiró F Battastini AMO Teixeira HF Koester ls 
 2017 validation hplc-uv method analysis kaempferol-loaded 
 nanoemulsion application vitro vivo test j Pharm 
 Biomed Anal 145:831 837 
 Cunha Gaubert Latxague L Dehay b 2021a plga-based nanoparticle 
 neuroprotective drug delivery neurodegenerative disease 
 Pharmaceutics 13:1042 
 Cunha Prévot g Mousli Y Barthélémy p Crauste-Manciet S Dehay b 
 Desvergnes V 2020 synthesis intracellular uptake rhodamine- 
 nucleolipid conjugate nanoemulsion vehicle acs omega 5:5815 5823 
 Cunha S Forbes b Sousa Lobo JM Silva ac 2021b improve drug 
 delivery alzheimer disease nose-to-brain delivery 
 nanoemulsion nanostructure lipid carrier nlc situ hydrogel 
 int J Nanomedicine 16:4373 4390 
 Dave BP Shah yb Maheshwari KG Mansuri KA Prajapati bs Postwala 
 HI Chorawala MR 2023 pathophysiological aspect therapeutic 
 armamentarium alzheimer disease recent trend future 
 development cell Mol Neurobiol 43:3847 3884 
 DiSabato DJ Quan N Godbout JP 2016 neuroinflammation devil 
 detail j Neurochem 139 Suppl 2:136 153 
 Dodson se Andersen OM Karmali V Fritz JJ Cheng D Peng J Levey ai 
 Willnow TE lah jj 2008 loss lr11/sorla enhance early pathology 
 mouse model amyloidosis evidence proximal role Alzheimer 
 disease j Neurosci 28:12877 12886 
 Dos Santos Rodrigues B Lakkadwala S Kanekiyo T Singh J 2019 development 
 screening brain-targeted lipid-based nanoparticle enhance cell 
 penetration gene delivery property int j Nanomedicine 14:6497 6517 
 Du Z Gao N Wang X ren J Qu x 2018 near-infrared switchable fullerene- 
 base synergy therapy alzheimer disease small e1801852 
 ege d 2021 action mechanism curcumin alzheimer disease 
 brain target delivery material basel 14:3332 
 elibol b Beker M terzioglu-usak S Dalli t Kilic U 2020 thymoquinone 
 administration ameliorate Alzheimer disease-like phenotype 
 promote cell survival hippocampus amyloid beta(1 42 infuse 
 rat model phytomedicine 79:153324 
 Elsori D Rashid g Khan NA Sachdeva p Jindal r Kayenat F Sachdeva B Kamal 
 MA Babker Fahmy SA 2023 nanotube breakthrough unveil 
 potential carbon nanotube dual therapeutic arsenal Alzheimer 
 disease brain tumor Oncol 13:1265347 
 Essa D Kondiah PPD Choonara ye pillay v 2020 design poly(lactide- 
 co-glycolide nanocarrier medical application Bioeng Biotechnol 
 8:48 
 Fanutza t Del Prete D Ford MJ Castillo PE d’adamio l 2015 app aplp2 
 interact synaptic release machinery facilitate transmitter 
 release hippocampal synapsis elife 4:e09743 
 Filadi r Pizzo p 2019 defective autophagy Alzheimer disease 
 calcium key Neural Regen Res 14:2081 2082 
 Gao h 2016 Progress perspective target nanoparticle brain 
 drug delivery acta pharm sin b 6:268 286 
 gómez-sintes r ledesma MD Boya p 2016 lysosomal cell death 
 mechanism aging ageing res rev 32:150 168 
 Gopalan D Pandey Udupa N Mutalik S 2020 receptor specific stimulus 
 responsive subcellular target approach effective therapy 
 Alzheimer role surface engineer nanocarrier j Control Release 
 319:183 200 
 Gorantla NV Chinnathambi S 2021 autophagic pathway clear tau 
 aggregate alzheimer disease cell Mol Neurobiol 41:1175 1181 
 Govindarajan K Kar S 2023 detection β-amyloid aggregates/plaque 
 5xfad mouse label native plga nanoparticle implication 
 diagnosis alzheimer disease j nanobiotechnology 21:216 
 gregori M Masserini M Mancini S 2015 nanomedicine treatment 
 Alzheimer disease nanomedicine Lond 10:1203 1218 
 Gupta J Fatima MT Islam Z Khan RH Uversky VN Salahuddin p 2019 
 nanoparticle formulation diagnosis therapy alzheimer 
 disease int j Biol Macromol 130:515 526 
 Hassan N Cordero ML Sierpe R Almada M Juárez J Valdez M Riveros 
 Vargas E Abou-Hassan Ruso JM Kogan MJ 2018 peptide functionalize 
 magneto-plasmonic nanoparticle obtain microfluidic inhibition 
 β-amyloid aggregation j Mater Chem b 6:5091 5099 
 Heneka MT Kummer MP Latz E 2014 innate immune activation 
 neurodegenerative disease nat rev Immunol 14:463 477 
 Hettiarachchi sd zhou y seven E Lakshmana MK Kaushik AK Chand hs 
 Leblanc rm 2019 nanoparticle-mediated approach Alzheimer 
 disease pathogenesis diagnosis therapeutic j Control Release 
 314:125 140 
 Hong S Beja-Glasser VF Nfonoyim BM Frouin Li S Ramakrishnan S Merry 
 KM Shi Q Rosenthal barre ba Lemere Selkoe DJ Stevens b 2016 
 Complement microglia mediate early synapse loss alzheimer mouse 
 model science 352:712 716 
 Hou X Watzlawik JO Fiesel FC Springer W 2020 Autophagy Parkinson 
 disease j Mol Biol 432:2651 2672 
 Hu M Li p Wang C Feng X Geng Q Chen W Marthi M Zhang W Gao C 
 Reid W Swanson J Du W Hume RI Xu h 2022 Parkinson disease-risk 
 protein tmem175 proton-activated proton channel lysosome cell 
 185:2292 2308.e20 
 Huang N Lu S Liu XG Zhu J Wang YJ Liu RT 2017 plga nanoparticle 
 modify bbb-penetrating peptide co-delivere aβ generation 
 inhibitor curcumin attenuate memory deficit neuropathology 
 Alzheimer disease mouse oncotarget 8:81001 81013 
 Hung C Livesey FJ 2021 endolysosome autophagy dysfunction 
 alzheimer disease autophagy 17:3882 3883 
 Hung C Tuck E Stubbs V van der Lee sj aalfs c van Spaendonk R schelten p 
 Hardy J Holstege h Livesey FJ 2021 sorl1 deficiency human excitatory 
 neuron cause app-dependent defect endolysosome-autophagy 
 network cell rep 35:109259 
 Kametani F Hasegawa M 2018 reconsideration amyloid hypothesis 
 tau hypothesis alzheimer disease Neurosci 12:25 
 Karami Z Saghatchi Zanjani MR Hamidi m 2019 nanoemulsion cns drug 
 delivery recent development impact challenge drug Discov Today 
 24:1104 1115 
 Karthivashan g Ganesan p Park sy Kim JS Choi dk 2018 therapeutic 
 strategy nano-drug delivery application management ageing 
 Alzheimer disease drug deliv 25:307 320 
 Klein M Hermey g 2023 converging link adult-onset 
 neurodegenerative Alzheimer disease early life neurodegenerative 
 neuronal ceroid lipofuscinosis Neural Regen Res 18:1463 1471 
 koh jy Kim HN Hwang jj Kim YH Park se 2019 lysosomal dysfunction 
 proteinopathic neurodegenerative disorder possible therapeutic role 
 camp zinc mol Brain 12:18 
 Krishnan S Shrestha Y Jayatunga DPW Rea S Martins R bharadwaj p 2020 
 Activate inhibit implication autophagy modulation therapeutic 
 strategy alzheimer disease int J Mol Sci 21:6739 
 Kumar M Misra Mishra AK Mishra p Pathak K 2008a Mucoadhesive 
 nanoemulsion-based intranasal drug delivery system olanzapine 
 brain targeting j Drug Target 16:806 814 
 Kumar M Misra Babbar AK Mishra AK Mishra p Pathak K 2008b 
 intranasal nanoemulsion base brain targeting drug delivery system 
 risperidone int j Pharm 358:285 291 
 Kumar S Ali J Baboota S 2016 Design Expert ® support optimization 
 predictive analysis selegiline nanoemulsion olfactory region 
 enhance behavioural performance Parkinson disease nanotechnology 
 27:435101 
 lai SSM Ng KY Koh ry Chok KC Chye sm 2021 endosomal-lysosomal 
 dysfunction Alzheimer disease pathogenesis therapeutic 
 intervention metab Brain Dis 36:1087 1100 
 Lee jh Yu WH Kumar Lee S Mohan PS peterhoff cm Wolfe dm martinez- 
 Vicente M Massey ac Sovak g Uchiyama Y Westaway D Cuervo 
 Nixon ra 2010 lysosomal proteolysis autophagy require presenilin 1 
 disrupt alzheimer-related ps1 mutation cell 141:1146 1158 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 438   ｜neural REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Lee JH McBrayer MK Wolfe dm Haslett LJ Kumar Sato Y Lie pp Mohan p 
 Coffey ee Kompella U Mitchell CH lloyd-evans E Nixon ra 2015 Presenilin 
 1 maintain lysosomal ca(2 + homeostasis trpml1 regulate vatpase- 
 mediated lysosome acidification cell rep 12:1430 1444 
 Lee jh Yang DS goulbourne cn m e Stavrides p Pensalfini Chan h 
 Bouchet-Marquis c Bleiwas C Berg MJ Huo C Peddy J Pawlik M Levy E 
 Rao M Staufenbiel M Nixon ra 2022 faulty autolysosome acidification 
 Alzheimer disease mouse model induce autophagic build-up Aβ 
 neuron yield senile plaque nat Neurosci 25:688 701 
 Li t Yin L Kang X Xue W Wang N Zhang J yuan p Lin L Li y 2022 tfeb 
 acetylation promote lysosome biogenesis ameliorate Alzheimer 
 disease-relevant phenotype mouse j Biol Chem 298:102649 
 Li Y law SM Miles LA Wiley JS Huang X Masters CL Gu BJ 2021 Genomics 
 Alzheimer disease implicate innate adaptive immune system 
 Cell Mol Life Sci 78:7397 7426 
 Liao MC Van Nostrand 2010 degradation soluble fibrillar 
 amyloid beta-protein matrix metalloproteinase mt1-mmp vitro 
 Biochemistry 49:1127 1136 
 Liao W Liu Z Zhang T Sun S Ye J Li Z Mao L ren j 2018 enhancement 
 anti-inflammatory property nobiletin macrophage nano- 
 emulsion preparation j Agric Food Chem 66:91 98 
 Lo CH Zeng J 2023 defective lysosomal acidification new prognostic 
 marker therapeutic target neurodegenerative disease transl 
 Neurodegener 12:29 
 Lohan S Raza K Mehta SK Bhatti GK Saini S Singh b 2017 Anti-Alzheimer 
 potential berberine surface decorate multi-walled carbon 
 nanotube preclinical evidence int j Pharm 530:263 278 
 Lyman M Lloyd DG Ji X Vizcaychipi MP ma d 2014 neuroinflammation 
 role consequence Neurosci Res 79:1 12 
 Malampati S Song JX chun-kit Tong b Nalluri Yang CB Wang Z 
 Gopalkrishnashetty Sreenivasmurthy S Zhu Z Liu J Su C Krishnamoorthi S 
 Iyaswamy Cheung KH Lu JH Li 2020 targeting aggrephagy 
 treatment alzheimer disease cell 9:311 
 Martins C Sousa F Araújo F sarmento b 2018 functionalizing PLGA 
 PLGA derivative drug delivery tissue regeneration application adv 
 Healthc Mater 7:1701035 
 Masood F 2016 polymeric nanoparticle target drug delivery system 
 cancer therapy mater Sci Eng c Mater Biol Appl 60:569 578 
 McGuire c Stransky L Cotter K Forgac M 2017 regulation v-atpase 
 activity Biosci Landmark Ed 22:609 622 
 Meng Q Wang Hua H Jiang Y Wang Y mu H Wu Z Sun K 2018 
 intranasal delivery huperzine brain lactoferrin-conjugated 
 n-trimethylated chitosan surface-modified plga nanoparticle 
 treatment alzheimer disease int j Nanomedicine 13:705 718 
 Milosch N tanriöver g Kundu rami françois jc Baumkötter F Weyer 
 sw Samanta Jäschke Brod F Buchholz CJ Kins S Behl c Müller UC 
 Kögel d 2014 holo-app g-protein-mediated signaling require 
 sappα-induce activation akt survival pathway cell death Dis 
 5:e1391 
 Mir M Ahmed N Rehman au 2017 recent application plga base 
 nanostructure drug delivery colloid surf b biointerface 159:217 231 
 Mishra Kim HJ Shin AH Thayer SA 2012 synapse loss induce 
 interleukin-1β require pre- post-synaptic mechanism j Neuroimmune 
 Pharmacol 7:571 578 
 Mohajeri M behnam b Barreto GE Sahebkar 2019 carbon nanomaterial 
 amyloid-beta interaction potential detection treatment 
 Alzheimer disease Pharmacol Res 143:186 203 
 musa sh Basri M Masoumi hr Karjiban ra malek EA Basri H Shamsuddin 
 af 2013 formulation optimization palm kernel oil ester nanoemulsion- 
 load chloramphenicol suitable meningitis treatment colloid 
 Surf b biointerface 112:113 119 
 Mustaly-Kalimi S Gallegos W Marr ra gilman-sachs Peterson DA Sekler 
 Stutzmann GE 2022 protein mishandling impaired lysosomal 
 proteolysis generate calcium dysregulation Alzheimer 
 disease proc natl Acad Sci U S 119:e2211999119 
 Nixon ra Yang ds 2012 Autophagy neuronal cell death neurological 
 disorder cold Spring Harb Perspect Biol 4:a008839 
 Ouyang QQ Zhao S Li sd song c 2017 application chitosan 
 chitooligosaccharide derivative treatment Alzheimer 
 disease Mar drug 15:322 
 Pandey YR Kumar S Gupta bk Ali J Baboota S 2016 intranasal delivery 
 paroxetine nanoemulsion olfactory region management 
 depression formulation behavioural biochemical estimation 
 Nanotechnology 27:025102 
 Pangeni r Sharma S Mustafa g Ali J Baboota S 2014 vitamin e load 
 resveratrol nanoemulsion brain targeting treatment 
 Parkinson disease reduce oxidative stress nanotechnology 
 25:485102 
 Pathak R Dash rp Misra M Nivsarkar M 2014 role mucoadhesive 
 polymer enhance delivery nimodipine microemulsion brain 
 intranasal route acta pharm sin b 4:151 160 
 Paul PS cho JY Wu Q Karthivashan g Grabovac E Wille H Kulka M Kar 
 S 2022 unconjugated plga nanoparticle attenuate temperature- 
 dependent β-amyloid aggregation protect neuron toxicity 
 implication alzheimer disease pathology j Nanobiotechnology 20:67 
 Polito VA Li H Martini-Stoica h Wang b Yang L Xu y swartzlander DB 
 Palmieri M di Ronza Lee VM Sardiello M Ballabio Zheng H 2014 
 selective clearance aberrant tau protein rescue neurotoxicity 
 transcription factor eb embo Mol Med 6:1142 1160 
 Prévot g soria fn Thiolat ML Daniel J verlhac JB blanchard-desce m 
 Bezard E Barthélémy p Crauste-Manciet S Dehay b 2018 harness 
 lysosomal ph plga nanoemulsion treatment lysosomal- 
 related neurodegenerative disease bioconjug Chem 29:4083 4089 
 Quick JD Silva C Wong JH lim kl Reynolds R Barron Zeng J Lo CH 
 2023 lysosomal acidification dysfunction microglia emerge 
 pathogenic mechanism neuroinflammation neurodegeneration j 
 Neuroinflammation 20:185 
 Rao MV McBrayer MK Campbell J Kumar Hashim Sershen H Stavrides 
 ph Ohno M Hutton M Nixon ra 2014 specific calpain inhibition 
 calpastatin prevent tauopathy neurodegeneration restore 
 normal lifespan tau p301l mouse j Neurosci 34:9222 9234 
 Rezvantalab S Drude ni Moraveji MK Güvener N Koons EK Shi Y lammer 
 t Kiessling F 2018 plga-based nanoparticle cancer treatment 
 Pharmacol 9:1260 
 Rocha CV gonçalve V da Silva MC Bañobre-López M Gallo J 2022 plga- 
 base composite biomedical application int J Mol Sci 
 23:2034 
 Root J Merino p nuckol Johnson M Kukar t 2021 lysosome dysfunction 
 cause neurodegenerative disease lesson frontotemporal 
 dementia amyotrophic lateral sclerosis Neurobiol Dis 154:105360 
 Sakhrani NM padh h 2013 Organelle target level drug targeting 
 drug Des Devel Ther 7:585 599 
 Salminen Kaarniranta K Kauppinen Ojala J Haapasalo Soininen H 
 Hiltunen M 2013 impaired autophagy app processing Alzheimer 
 disease potential role beclin 1 interactome prog Neurobiol 106- 
 107:33 54 
 sánchez-navarro m Giralt E Teixidó m 2017 blood-brain barrier peptide 
 shuttle Curr opin Chem Biol 38:134 140 
 Sannerud R et al. 2016 restricted location psen2/γ-secretase determine 
 substrate specificity generate intracellular aβ pool cell 166:193- 
 208 
 Sarkar C Jones JW Hegdekar N Thayer JA Kumar Faden ai Kane MA 
 Lipinski MM 2020 pla2g4a/cpla2-mediated lysosomal membrane 
 damage lead inhibition autophagy neurodegeneration 
 brain trauma autophagy 16:466 485 
 selkoe DJ Hardy J 2016 amyloid hypothesis alzheimer disease 
 25   year embo Mol Med 8:595 608 
 Shojaei S Suresh M Klionsky DJ labouta hi Ghavami S 2020a Autophagy 
 sars-cov-2 infection apossible smart targeting autophagy 
 pathway virulence 11:805 810 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
 NEURAL REGENERATION RESEARCH｜Vol 20｜No 2｜february 2025｜439 
 NEURAL REGENERATION research 
 www.nrronline.org 
 Review 
 Shojaei S Koleini N Samiei E Aghaei M Cole LK Alizadeh J Islam MI 
 Vosoughi AR Albokashy M Butterfield y Marzban H Xu F Thliveris J 
 Kardami E Hatch GM Eftekharpour E Akbari M hombach-klonisch S 
 Klonisch t Ghavami S 2020b simvastatin increase temozolomide-induced 
 cell death target fusion autophagosome lysosome febs 
 J 287:1005 1034 
 sly ws vogler c 2002 brain-directed gene therapy lysosomal storage 
 disease go blood- brain barrier proc natl Acad Sci U S 
 99:5760 5762 
 small SA petsko GA 2015 Retromer alzheimer disease parkinson disease 
 neurological disorder nat rev Neurosci 16:126 132 
 Sood S Jain K Gowthamarajan K 2014 optimization curcumin 
 nanoemulsion intranasal delivery design experiment 
 toxicity assessment colloid surf b Biointerfaces 113:330 337 
 Soria Lopez JA González HM léger gc 2019 alzheimer disease handb 
 Clin Neurol 167:231 255 
 tian X Shi Yin H Wang Y Liu Q Chen W Wu J 2022 nanomaterial 
 respond lysosomal function tumor treatment cell 11:3348 
 twarowski b Herbet M 2023 inflammatory process alzheimer disease- 
 pathomechanism diagnosis treatment review int J Mol Sci 24:6518 
 Udayar V Chen Y Sidransky E Jagasia r 2022 lysosomal dysfunction 
 neurodegeneration emerge concept method trend Neurosci 
 45:184 199 
 Unnisa Greig NH Kamal ma 2023 nanotechnology-based gene therapy 
 credible tool treatment alzheimer disease neural Regen Res 
 18:2127 2133 
 Van Acker ZP Bretou M Annaert W 2019 endo-lysosomal dysregulation 
 late-onset Alzheimer disease impact genetic risk factor mol 
 Neurodegener 14:20 
 Van Acker ZP Perdok Bretou M Annaert W 2021 microglial lysosomal 
 system Alzheimer disease guardian proteinopathy age res 
 rev 71:101444 
 Vest RT Chou CC Zhang H haney ms Li L Laqtom NN Chang b Shuken S 
 Nguyen Yerra L Yang AC Green C Tanga M Abu-Remaileh M Bassik 
 MC Frydman J Luo J wyss-coray t 2022 small molecule c381 target 
 lysosome reduce inflammation ameliorate disease model 
 neurodegeneration proc natl Acad Sci U S 119:e2121609119 
 Vilella Belletti d Sauer AK Hagmeyer S sarowar t Masoni M Stasiak N 
 Mulvihill jje Ruozi b Forni F Vandelli MA Tosi g Zoli m Grabrucker 
 2018 reduce plaque size inflammation app23 mouse model 
 Alzheimer disease chronic application polymeric nanoparticle 
 cns target zinc delivery j Trace Elem Med Biol 49:210 221 
 Vingtdeux v dreses-werringloer U Zhao H Davies p Marambaud p 2008 
 therapeutic potential resveratrol alzheimer disease bmc Neurosci 9 
 Suppl 2:s6 
 Viswanathan K Hoover DJ Hwang J Wisniewski ML Ikonne Bahr BA 
 Wright DL 2012 nonpeptidic lysosomal modulator derive z-phe- 
 ala-diazomethylketone treat protein accumulation disease acs 
 Med Chem Lett 3:920 924 
 Wang F gómez-sintes r Boya p 2018 lysosomal membrane 
 permeabilization cell death traffic 19:918 931 
 Wang J Cheng Y Chen L zhu t Ye K Jia C Wang H Zhu M Fan C mo x 
 2019 vitro vivo study electroactive reduce graphene oxide- 
 modify nanofiber scaffold peripheral nerve regeneration acta 
 Biomater 84:98 113 
 Wang X Zhou X Li g Zhang Y Wu Y Song W 2017 modification 
 trafficking app pathogenesis alzheimer disease Mol 
 Neurosci 10:294 
 Wang Y Wu Q Anand BG Karthivashan g Phukan g Yang J Thinakaran 
 g Westaway d Kar S 2020 significance cytosolic cathepsin d 
 Alzheimer disease pathology protective cellular effect plga 
 nanoparticle β-amyloid-toxicity Neuropathol Appl Neurobiol 
 46:686 706 
 whyte ls Lau AA Hemsley KM Hopwood jj sargeant tj 2017 endo- 
 lysosomal autophagic dysfunction drive factor Alzheimer 
 disease j Neurochem 140:703 717 
 Woon ck Hui WK Abas R Haron MH Das S Lin TS 2022 natural product- 
 base nanomedicine recent advance issue treatment 
 Alzheimer disease curr Neuropharmacol 20:1498 1518 
 Wu Q Karthivashan g nakhaei-nejad m Anand BG Giuliani F Kar S 2022 
 native plga nanoparticle regulate app metabolism protect neuron 
 β-amyloid toxicity potential significance alzheimer disease 
 pathology int j Biol Macromol 219:1180 1196 
 xi y Chen Y Jin Y Han g Song M Song t Shi Y Tao L Huang Z Zhou J 
 Ding y Zhang H 2022 versatile nanomaterial alzheimer disease 
 pathogenesis inspire disease-modifying therapy j Control Release 345:38- 
 61 
 xu y Propson NE Du S Xiong W Zheng H 2021 Autophagy deficiency 
 modulate microglial lipid homeostasis aggravate tau pathology 
 spreading proc natl Acad Sci U S 118:e2023418118 
 Xue W Zhang J Li y 2023 enhancement lysosome biogenesis 
 potential therapeutic approach neurodegenerative disease neural 
 Regen res 18:2370 2376 
 Xue X Wang LR Sato Y Jiang Y Berg M Yang DS Nixon ra Liang xj 2014 
 single-walled carbon nanotube alleviate autophagic/lysosomal defect 
 primary glia mouse model alzheimer disease nano Lett 
 14:5110 5117 
 Yang DS Stavrides p Mohan PS Kaushik S Kumar Ohno M schmidt sd 
 Wesson DW Bandyopadhyay U Jiang Y Pawlik M peterhoff cm Yang AJ 
 Wilson DA St George-Hyslop p Westaway d Mathews PM Levy E Cuervo 
 Nixon ra 2011 therapeutic effect remediate autophagy failure 
 mouse model alzheimer disease enhance lysosomal proteolysis 
 Autophagy 7:788 789 
 Yang Z Zhang Y Yang Y Sun L Han D Li H Wang c 2010 pharmacological 
 toxicological target organelle safe use single-walled carbon 
 nanotube drug carrier treat alzheimer disease nanomedicine 
 6:427 441 
 Yin t Liu Y Ji W Zhuang J Chen X Gong b Chu J Liang W Gao J Yin Y 
 2023a engineer mesenchymal stem cell-derived extracellular vesicle 
 state-of-the-art multifunctional weapon Alzheimer disease 
 theranostic 13:1264 1285 
 Yin X Zhou H Zhang M Su J Wang X Li S Yang Z Kang Z zhou r 2023b 
 C(3)N nanodot inhibit aβ peptide aggregation pathogenic path 
 Alzheimer disease nat Commun 14:5718 
 Yu C Meng J Chen J Tang X 2009 preparation ergoloid mesylate 
 submicron emulsion enhance nasal absorption reduce nasal 
 ciliotoxicity int j Pharm 375:16 21 
 Yusuf M Khan M alrobaian MM Alghamdi SA Warsi MH Sultana S Khan 
 ra 2021 brain target polysorbate-80 coat plga thymoquinone 
 nanoparticle treatment alzheimer disease biomechanistic 
 insight j Drug Deliv Sci Technol 61:102214 
 Yuyama K Sun H Usuki S Sakai S Hanamatsu H Mioka t Kimura N Okada M 
 Tahara h Furukawa J Fujitani N Shinohara y Igarashi y 2015 potential 
 function neuronal exosome sequester intracerebral amyloid-β 
 peptide febs Lett 589:84 88 
 Zenaro E piacentino g constantin g 2017 blood-brain barrier 
 Alzheimer disease neurobiol Dis 107:41 56 
 Zhao M Jiang xf Zhang HQ Sun JH Pei h Ma LN Cao y Li h 2021 
 interaction glial cell blood-brain barrier role 
 Alzheimer disease ageing res rev 72:101483 
 c-editor Zhao m s-editor Yu J Li CH l-editor Yu J Song lp 
 t-editor Jia Y 
 Downloaded http://journals.lww.com/nrronline bhdmf5ephkav1zeoum1tqfn4a+kjlhezgbsiho4xmi0hcyw 
 cx1awnyqp/ilqrhd3i3d0odryi7tvsfl4cf3vc4/oavpdda8kkgkv0ymy+78= 06/01/2024 
